Hormonal
Incretin receptor agonists (IRAs), including GLP-1RAs and dual GIP/GLP-1RAs, reduce the risk of major adverse cardiovascular events (MACE) and improve lipid profiles and blood pressure in patients with type 2 diabetes.
If you have Type 2 Diabetes and are at risk for heart disease, ask your doctor about GLP-1 receptor agonists (like liraglutide, semaglutide, or dulaglutide). These medications not only help control blood sugar but have been proven in large studies to significantly reduce the risk of heart attacks, strokes, and cardiovascular death. They also help lower blood pressure and improve cholesterol levels. While they are often injectable (with some oral options available), the cardiovascular protection they offer is a major benefit for patients with existing heart conditions.
IRAs help in managing atherosclerotic risk factors by improving blood glucose, blood lipids, and reducing blood pressure (11, 12)... Long-term multinational and multicenter CV outcome trials (CVOTs) have generated substantial evidence supporting the use of GLP-1RAs in effectively lowering the risk of CV events (Table 2).
Why this rating
The paper cites multiple large-scale, randomized controlled trials (LEADER, SUSTAIN-6, REWIND) demonstrating statistically significant reductions in MACE.
Source
Anti-atherosclerotic effect of incretin receptor agonists
Xin Wang et al. · Frontiers in Endocrinology · 2024
DOI 10.3389/fendo.2024.1463547
More from this paper
- GLP-1 receptor agonists protect endothelial function by reducing oxidative stress, inhibiting inflammation, and promoting nitric oxide (NO) production.Moderate
- GLP-1 receptor agonists reduce foam cell formation and promote anti-inflammatory M2 macrophage polarization, thereby stabilizing atherosclerotic plaques.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →